SCHEMBL1150892

SCHEMBL1150892

COC(=O)c1cc(F)ccc1CC(Br)C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.39
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
KMT2A Q03164 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
DPP4 P27487 2/20 0.34
PDK2 Q15119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150819 0.80 ALDH1A1 (0.51) SLC6A3KMT2AMAPTTSHRALDH1A1
SCHEMBL29604367 0.78 SLC6A4 (0.44) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL1435113 0.78 SLC6A4 (0.44) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL19245119 0.78 SLC6A4 (0.46) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL1150839 0.76 FFAR4 (0.41) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL2076694 0.75 SLC6A4 (0.44) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL2292462 0.75 SLC6A4 (0.44) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL13714155 0.74 SLC6A4 (0.41) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
Hydrochloric Acid SCHEMBL1977404 0.74 SLC6A4 (0.43) PLA2G2ASLC6A4SLC6A3FFAR4NPC1
SCHEMBL26712654 0.74 PDGFRB (0.46) PLA2G2ASLC6A4SLC6A3FFAR4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291377-B1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2015-02-18 EP disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 PLA2G2A 4750/4885SLC6A4 791/4885SLC6A3 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.